Duearity's sales in December 2023 amounted to SEK 450,000, which is the best sales result for a single month so far since the company received CE marking for the EU and FDA approval for the USA earlier this year. The company started three and a half years ago and has since developed a medical tinnitus product, obtained market approval in the EU and in the USA and started sales.
During the autumn, Duearity implemented a strategic change which means that the company switched to selling Tinerity G1 only via distributors in Europe. The distributors have been working purposefully with marketing and sales since the beginning of autumn, which is now giving the result that the new strategy was intended to give.
- The distributors' experiences from ear-nose-throat market and their networks are beginning to give results and we are receiving very positive feedback from clinics in both Europe and the US. Our assessment is that the sales revenue will increase from quarter to quarter. Our focus is on increasing sales and achieving break-even on a quarterly basis during the second half of 2024, says Fredrik Westman, CEO of Duearity AB.
The company has currently entered into agreements with five distributors covering nine countries in the EU. Furthermore, Duearity is in discussions with additional distributors in Europe and the US as well as with distributors outside the EU and the US. There are several qualified distributors who want to enter into agreements with Duearity and the company's focus is now on making use of the positive trend and that the company achieves its goals for the coming year.